Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Britain Courts Anthropic Amid US Defense Department Dispute 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Apple Turns 50: From Garage Startup to AI Crossroads 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
NEW YORK, Jan. 14, 2016 (GLOBE NEWSWIRE) -- Microlin Bio, Inc., a development stage biotechnology company focused on the development of microRNA based therapeutics for cancer, today announced the change of its trading symbol from AMIB to MICB. The change will take effect on January 14, 2016.
The new trading symbol, which is more closely aligned with the Company’s name, is intended to strengthen the Microlin Bio brand and increase its profile within the investment community.
Beginning January 14, 2016 all information, including stock trading, SEC filings, and market data related to Microlin Bio, will be reported under the new ticker symbol, “MICB.” The CUSIP for company’s common stock will remain unchanged. Outstanding stock certificates are not affected by the symbol change and will not need to be exchanged.
About microRNA
MicroRNAs are recently discovered naturally occurring RNA molecules (composed of 19 to 25 nucleotides) that do not encode proteins but instead regulate gene expression and various biological pathways. The improper balance of microRNAs are linked to many diseases, including cancer. As such, replacement or inhibition of deregulated microRNAs may act as a potent means to treat cancers.
About Microlin Bio, Inc.
Microlin Bio, Inc. is a development stage biotechnology company focused primarily on the development of microRNA based therapeutics to treat cancer from technologies licensed from Ohio State University. This includes over 138 pending patent applications and 132 granted patents covering numerous microRNAs. For more information, please visit www.microlinbio.com.
Microlin Bio Forward-Looking Statements
This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect Microlin Bio’s business and Microlin Bio undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
The Ruth Group Lee Roth (investors) [email protected] (646) 536-7012 Ashley Brown (media) [email protected] (646)536-7002
